Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 20 symbols : Nvs save search
Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: -1.03%
H: 0.24%
C: -0.15%
BGNE | $129.995 -1.49% 110K
|
Health Technology
|
| O: 8.83%
H: 0.11%
C: -4.16%
novartis license immunotherapy therapy collaboration
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 0.56%
H: 0.3%
C: 0.19%
fda application license biosimilar
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
Published: 2021-12-20 (Crawled : 12:30) - biospace.com/
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: -1.03%
H: 0.24%
C: -0.15%
BGNE | $129.995 -1.49% 110K
|
Health Technology
|
| O: 8.83%
H: 0.11%
C: -4.16%
novartis china collaboration
Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
Published: 2021-12-20 (Crawled : 07:00) - globenewswire.com
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: -1.03%
H: 0.24%
C: -0.15%
qge031 novartis urticaria
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.